GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Agilent Technologies Inc (NYSE:A) » Definitions » GF Value

Agilent Technologies (Agilent Technologies) GF Value : $142.43 (As of Apr. 26, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Agilent Technologies GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

  1. Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
  2. GuruFocus adjustment factor based on the company’s past returns and growth.
  3. Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-04-26), Agilent Technologies's share price is $136.37. Agilent Technologies's GF Value is $142.43. Therefore, Agilent Technologies's Price-to-GF-Value for today is 0.96.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Agilent Technologies is Fairly Valued.


Agilent Technologies  (NYSE:A) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)Predictable Companies that possibly be Value Traps
Significantly OvervaluedPredictable Companies which are Significantly Overvalued
Modestly OvervaluedPredictable Companies which are Modestly Overvalued
Fairly ValuedPredictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Agilent Technologies's Price-to-GF-Value for today is calculated as

Price-to-GF-Value=Share Price/GF Value
=136.37/142.43
=0.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Agilent Technologies GF Value Related Terms

Thank you for viewing the detailed overview of Agilent Technologies's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Agilent Technologies (Agilent Technologies) Business Description

Traded in Other Exchanges
Address
5301 Stevens Creek Boulevard, Santa Clara, CA, USA, 95051
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab (consisting of consumables and services related to life science and applied tools), and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. and China representing the largest country concentrations.
Executives
Philip Binns officer: Senior Vice President 5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Rodney Gonsalves officer: V.P., Corporate Controller 5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Henrik Ancher-jensen officer: Sr. Vice President 5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Michael R. Mcmullen officer: CEO and President 5301 STEVENS CREEK BLVD., MS 1A-LC, SANTA CLARA CA 95051
George A Scangos director C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083
Otis W Brawley director 5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Mikael Dolsten director 5 GIRALDA FARMS, MADISON NJ 07940
Mala Anand director C/O COTIVITI HOLDINGS, INC., 115 PERIMETER CENTER PLACE, SUITE 700, ATLANTA GA 30346
Sue H. Rataj director C/O CABOT CORPORATION, TWO SEAPORT LANE, SUITE 1300, BOSTON MA 02210
Dow R Wilson director VARIAN MEDICAL SYSTEMS INC, 3100 HANSEN WAY MAIL STOP E327, PALO ALTO CA 94304
Boon Hwee Koh director C/O AGILENT TECHNOLOGIES, 5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Heidi Fields director 5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Hans Edgar Bishop director 60 WEST 66TH STREET, 26A, NEW YORK NY 10023
Daniel K Podolsky director 5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Padraig Mcdonnell officer: Senior Vice President 5301 STEVENS CREEK BLVD, SANTA CLARA CA 95051